Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome

详细信息    查看全文

• 作者：Susana H. Belli ; Mabel N. Graffigna ; Adriana Oneto ; Patricia Otero ; Leon Schurman ; Oscar A. Levalle
• 刊名：Fertility and Sterility
• 出版年：2004
• 出版时间：March 2004
• 年：2004
• 卷：81
• 期：3
• 页码：624-629
• 全文大小：110 K

文摘

<h3 class=""h3"">Objectiveh3>To evaluate the effects of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome (PCOS).<h3 class=""h3"">Designh3>

Prospective study.<h3 class=""h3"">Settingh3>

Women with PCOS attending as outpatients of the Endocrine Division, Hospital Durand, Buenos Aires.<h3 class=""h3"">Patient(s)h3>

Twenty-four insulin-resistant women with PCOS.<h3 class=""h3"">Intervention(s)h3>

Hormonal evaluations and a standardized oral glucose tolerance test before and after a 3-month trial of 4 mg of rosiglitazone daily.<h3 class=""h3"">Main outcome measure(s)h3>

Serum LH, FSH, T, IGF-1, IGFBP-1, IGFBP-3, leptin, 17α-hydroxyprogesterone, insulin, and glucose concentrations. The area under insulin curve (AUC-insulin), the HOMA index (insulin resistance), the QUICKI index (insulin sensitivity), and the β-cell function were calculated. Body mass index (BMI) and the waist/hip ratio were evaluated.<h3 class=""h3"">Result(s)h3>

A significant decrease was observed in serum fasting insulin, AUC insulin, HOMA index, β-cell function, IGF-1, LH, and waist/hip ratio. The QUICKI index and IGFBP-1 increased significantly. Serum sex hormone–binding globulin, androgens, leptin, IGFBP-3, and BMI remained unchanged. Twenty-two of 23 females had their menses restored, and three patients became pregnant. One patient was excluded because she became pregnant at the second month.<h3 class=""h3"">Conclusion(s)h3>

Associated with the decrease in LH, rosiglitazone improved insulin-resistance parameters and normalized the menstrual cycle, which suggests that this drug could improve the endocrine-reproductive condition in insulin-resistant women with PCOS.